Flythe JE, Forfang D, Gedney N, White DM, Wilkie C, Cavanaugh K, Harris RC, Unruh M, Squillaci G, West M, Mansfield C, Soloe CS, Treiman K, Wood D, Hurst FP, Neuland C, Saha A, Sheldon M, Tarver ME. Development of a patient preference survey for wearable kidney replacement therapy devices. Kidney360. 2022 May 5;3(7):1197-209. doi: 10.34067/KID.0001862022
Dundas SJ, von Haefen RH, Mansfield C. Recreation costs of endangered species protection: evidence from Cape Hatteras National Seashore. Marine Resource Economics. 2018 Jan;33(1):1-25. doi: 10.1086/694752
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Myers KH, Parsons GR, Edwards PET. Measuring the recreational use value of migratory shorebirds on the Delaware Bay. Marine Resource Economics. 2010 Apr 23;25(3):247-64.
French M, Neighbors D, Carswell L, Williams R, Bush L. A model for estimating industry compliance costs of food labeling regulations. Agribusiness: An International Journal. 1993;8(2):165-86.